前列腺癌启动雄激素受体通路抑制剂后代谢功能障碍的发生情况
结果显示,联合治疗启动后第一年MetS累积发病率稳步上升至近40%,且随年龄组而异,70-79岁组发病率最高。研究提示应超越肿瘤特异性结局,早期监测代谢功能障碍。
要点
- ADT联合ARPI启动后第一年MetS累积发病率近40%,需早期监测。
- 70-79岁患者MetS发病率最高,达51.7事件/1000人月(95%CI 50.7-53.9)。
- 高血压是最常记录的代谢组分结局,代谢关联随年龄和ARPI类型而异。
核心结论
- ADT联合ARPI启动后第一年内代谢异常频繁被记录,MetS累积发病率近40%。
- 建议监测超越肿瘤特异性结局,纳入代谢功能障碍的早期检测,理想情况下通过多学科照护实现。
研究设计与样本
- 回顾性队列研究,使用Epic Cosmos国家去标识化健康记录数据集,纳入2014年1月至2025年9月接受ADT-ARPI治疗的成人前列腺癌患者,每人随访至12个月。
主要发现
- ADT联合ARPI启动后第一年MetS累积发病率稳步上升至近40%,且随年龄组而异。
- 高血压是最常记录的代谢组分结局。
- 70-79岁患者MetS发病率最高,为51.7事件/1000人月(95%CI 50.7-53.9)。
- 探索性分析观察到代谢结局随ARPI类型存在异质性。
关键数值与推荐
- MetS累积发病率近40%(第一年)。
- 70-79岁组MetS发病率51.7事件/1000人月(95%CI 50.7-53.9)。
临床怎么用
- 对接受ADT联合ARPI治疗的前列腺癌患者,应在治疗早期监测代谢功能障碍,包括血压、血糖、血脂和体重等组分。
- 考虑通过多学科照护模式管理心血管代谢风险。
局限性
- 回顾性队列设计,使用去标识化健康记录数据,可能存在记录不完整或错分。
- 随访时间限于12个月,无法评估长期代谢结局。
- ARPI类型异质性分析为探索性,需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Metabolic syndrome (MetS) includes obesity, insulin resistance, hypertension, and dyslipidemia. While androgen deprivation therapy (ADT) is associated with an increased risk of dyslipidemia, adiposity, and MetS, evidence is limited on the occurrence and timing of metabolic dysfunction among men receiving concurrent androgen receptor pathway inhibitor (ARPI) therapy and whether patterns vary by age. OBJECTIVE: To characterize the occurrence and rate of MetS during the first year following initiation of ADT-ARPI, examine associations with age and ARPI type, and evaluate component metabolic outcomes (secondary end points). DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study of adult patients from January 2014 to September 2025 with up to 12 months of follow-up per person used data from a national, deidentified health record dataset (Epic Cosmos) and included patients with prostate cancer who initiated treatment with ADT-ARPI (abiraterone acetate, enzalutamide, apalutamide, and darolutamide) without evidence of MetS or its components before treatment. Data were analyzed between October 2025 and January 2026 (further analyses were done with revisions through May 2026). EXPOSURE: Concurrent ADT and ARPI use, with index date defined as the first date of overlap between therapies. MAIN OUTCOMES AND MEASURES: New-onset MetS during the 12 months following the index date. Secondary outcomes included individual metabolic abnormalities. RESULTS: The cohort included 16 924 men with prostate cancer (mean [SD] age, 73.1 [9.1] y; 509 [3.0%] Asian individuals, 912 [5.4%] Hispanic individuals, 3562 [21.0%] non-Hispanic Black individuals, and 11 083 [65.5%] non-Hispanic White individuals). Medical ADT use predominated, and enzalutamide was the most frequently used ARPI. During the first year following initiation of concurrent ADT and ARPI therapy, the cumulative incidence of metabolic syndrome increased steadily, reaching nearly 40%, and varied by age group. Hypertension was the most frequently documented component outcome. Metabolic associations varied by age, with the highest incidence of metabolic syndrome among patients aged 70 to 79 years (51.7 events per 1000 person-months; 95% CI, 50.7-53.9). Heterogeneity in metabolic outcomes by ARPI type was observed in exploratory analyses. CONCLUSIONS AND RELEVANCE: This study found that while ARPIs are standard of care for advanced prostate cancer, metabolic abnormalities were frequently documented shortly after initiation of concurrent ADT and ARPI therapy. This suggests that monitoring should extend beyond cancer-specific outcomes to include early detection of metabolic dysfunction, ideally through multidisciplinary care. The early burden of metabolic abnormalities highlights the need to evaluate scalable interventions addressing cardiometabolic risk in men with prostate cancer.
引用
- Shaver AL, Zarrabi KK, Nikita N, et al. Metabolic Dysfunction After Initiation of Androgen Receptor Pathway Inhibitors in Prostate Cancer. JAMA Oncol. 2026. PMID: 42593785. doi:10.1001/jamaoncol.2026.2790
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。